GlassScriptPhysician profile
William C Park
NPI 1942458237
$3,211.61
in general payments reported to CMS, 2019-2025
23 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.74 · 2020: $88.43 · 2021: $1,293 · 2022: $260 · 2023: $256 · 2024: $545 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Alcon Vision LLC | $543.91 | 2024-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.14 | 2022-2023 | Relistor |
| Regeneron Healthcare Solutions, INC. | $155.64 | 2024-2025 | Eylea Hd |
| Abbvie INC. | $113.40 | 2024-2025 | |
| Astellas Pharma US INC | $98.25 | 2025 | Izervay |
| Bausch & Lomb Americas INC. | $96.48 | 2023-2024 | Vyzulta, Miebo, Envista Mx60 Iol |
| Abbott Laboratories | $88.43 | 2020 | |
| Grt US Holding, INC. | $83.05 | 2021-2022 | |
| Sight Sciences, INC. | $54.74 | 2019 | |
| Rxsight INC | $54.67 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| New World Medical,INC. | $54.48 | 2024 | Kahook Dual Blade, Streamline, Ahmed Glaucoma Valve |
| Scilex Pharmaceuticals INC. | $44.87 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $42.36 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $41.74 | 2024-2025 | Tecnis Simplicity, Catalys System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $40.91 | 2021 | |
| Allergan, INC. | $35.77 | 2022 | |
| Genentech USA, INC. | $29.23 | 2024 | Vabysmo |
| Dompe US, INC. | $24.70 | 2024 | Oxervate |
| Horizon Therapeutics Plc | $20.10 | 2023 | Tepezza |
| Harrow Eye, LLC | $16.02 | 2025 | |
| Cranial Technologies, INC | $15.99 | 2023 | Doc Band |
| Amgen INC. | $13.73 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.